JP2003517434A - ヒドロキシオメプラゾール組成物及びその使用 - Google Patents

ヒドロキシオメプラゾール組成物及びその使用

Info

Publication number
JP2003517434A
JP2003517434A JP2000546772A JP2000546772A JP2003517434A JP 2003517434 A JP2003517434 A JP 2003517434A JP 2000546772 A JP2000546772 A JP 2000546772A JP 2000546772 A JP2000546772 A JP 2000546772A JP 2003517434 A JP2003517434 A JP 2003517434A
Authority
JP
Japan
Prior art keywords
hydroxyomeprazole
pharmaceutically acceptable
acceptable salt
effective amount
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000546772A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003517434A5 (https=
Inventor
イー． エール，ウイリアム
エイ． ハンドレイ，ディーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of JP2003517434A publication Critical patent/JP2003517434A/ja
Publication of JP2003517434A5 publication Critical patent/JP2003517434A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2000546772A 1998-05-05 1999-05-05 ヒドロキシオメプラゾール組成物及びその使用 Pending JP2003517434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8425898P 1998-05-05 1998-05-05
US60/084,258 1998-05-05
PCT/US1999/009814 WO1999056746A1 (en) 1998-05-05 1999-05-05 Hydroxyomeprazole compositions and uses

Publications (2)

Publication Number Publication Date
JP2003517434A true JP2003517434A (ja) 2003-05-27
JP2003517434A5 JP2003517434A5 (https=) 2006-06-15

Family

ID=22183810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000546772A Pending JP2003517434A (ja) 1998-05-05 1999-05-05 ヒドロキシオメプラゾール組成物及びその使用

Country Status (9)

Country Link
US (2) US6294586B1 (https=)
EP (1) EP1082114B1 (https=)
JP (1) JP2003517434A (https=)
AT (1) ATE222764T1 (https=)
AU (1) AU748872B2 (https=)
CA (1) CA2330049A1 (https=)
DE (1) DE69902657T2 (https=)
ES (1) ES2182524T3 (https=)
WO (1) WO1999056746A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420435B1 (en) * 1999-11-01 2002-07-16 Joe S. Wilkins, Jr. Method for treating gastrointestinal disorders
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7041706B2 (en) * 2002-04-19 2006-05-09 Wilkins Jr Joe S Method for treating crohn's disease
WO2004064719A2 (en) * 2003-01-24 2004-08-05 State Of Israel, Ministry Of Agriculture Synergistic compositions and methods for potentiating anti-oxidative activity
WO2005032554A1 (en) 2003-10-03 2005-04-14 Astron Research Pvt. Ltd A novel transmucosal delivery system
ES2281292B1 (es) * 2006-03-08 2008-06-16 Quimica Sintetica S.A. Nuevas sales de esomeprazol. procedimiento de preparacion y composiciones farmaceuticas que las comprenden.

Also Published As

Publication number Publication date
WO1999056746A1 (en) 1999-11-11
EP1082114A1 (en) 2001-03-14
AU748872B2 (en) 2002-06-13
EP1082114B1 (en) 2002-08-28
US6294586B1 (en) 2001-09-25
ES2182524T3 (es) 2003-03-01
CA2330049A1 (en) 1999-11-11
AU3971699A (en) 1999-11-23
ATE222764T1 (de) 2002-09-15
US6498171B2 (en) 2002-12-24
DE69902657D1 (de) 2002-10-02
US20020010196A1 (en) 2002-01-24
DE69902657T2 (de) 2003-04-30

Similar Documents

Publication Publication Date Title
AU742620B2 (en) R-lansoprazole compositions and methods
US20010025107A1 (en) S-lansoprazole compositions and methods
US20050222211A1 (en) S(-)rabeprazole compositions and methods
US6174902B1 (en) R-rabeprazole compositions and methods
JP2003517434A (ja) ヒドロキシオメプラゾール組成物及びその使用
EP1098648B1 (en) Pharmaceutical compositions comprising hydroxylansoprazole and uses thereof
JP2002512262A (ja) Ｒ−レイブプラゾール組成物及び方法
US20060142346A1 (en) S-lansoprazole compositions and methods
AU2003268822A1 (en) R-raberprazole compositions and methods
AU2003257509A1 (en) S-rabeprazole compositions and methods
AU2003264624A1 (en) S-lansoprazole compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100427